The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Haaß, Wiltrud ^a   Stehle, Michael ^a   Nittka, Stefanie ^a   Giehl, Michelle ^a   Schrotz King, Petra ^b   Fabarius, Alice ^a   Hofmann, Wolf Karsten ^a   Seifarth, Wolfgang ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLIN B1; IMATINIB; PHOSPHOPROTEIN PHOSPHATASE 2A; SECURIN; SEPARASE;

ARTICLE; CANCER CELL CULTURE; CENTROSOME; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BLAST CRISIS; CELL CYCLE PROTEINS; CYCLIN B1; DRUG RESISTANCE, NEOPLASM; ENDOPEPTIDASES; FUSION PROTEINS, BCR-ABL; GENOMIC INSTABILITY; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTEIN PHOSPHATASE 2; PROTEOLYSIS; PYRIMIDINES; U937 CELLS;

EID: 84864561201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042863     Document Type: Article

References (54)

1. Sawyers CL, (1999) Chronic myeloid leukemia. N Engl J Med 340: 1330-1340.
2. Calabretta B, Perrotti D, (2004) The biology of CML blast crisis. Blood 103: 4010-4022.
3. Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A, (2011) Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 119: 530-539.
4. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
5. Hochhaus A, Schenk T, Erben P, Ernst T, La Rosee P, et al. (2009) Cause and management of therapy resistance. Best Pract Res Clin Haematol 22: 367-379.
6. Rosenhahn J, Weise A, Michel S, Hennig K, Hartmann I, et al. (2007) Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R. Int J Oncol 31: 121-128.
7. Schnittger S, Bacher U, Dicker F, Kern W, Alpermann T, et al. (2010) Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. Genes Chromosomes Cancer 49: 910-918.
8. Cortes J, O'Dwyer ME, (2004) Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 18: 671-684, x.
9. O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, et al. (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100: 1628-1633.
10. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, et al. (2010) Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116: 2673-2681.
11. Chan JY, (2011) A clinical overview of centrosome amplification in human cancers. Int J Biol Sci 7: 1122-1144.
12. Pihan GA, Wallace J, Zhou Y, Doxsey SJ, (2003) Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 63: 1398-1404.
13. Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, et al. (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A 99: 1978-1983.
14. Ganem NJ, Godinho SA, Pellman D, (2009) A mechanism linking extra centrosomes to chromosomal instability. Nature 460: 278-282.
15. Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, et al. (2005) Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 19: 1192-1197.
16. Weaver BA, Cleveland DW, (2007) Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 67: 10103-10105.
17. Giehl M, Fabarius A, Frank O, Erben P, Zheng C, et al. (2007) Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. Leukemia 21: 1971-1976.
18. Patel H, Gordon MY, (2009) Abnormal centrosome-centriole cycle in chronic myeloid leukaemia? Br J Haematol 146: 408-417.
19. Fabarius A, Giehl M, Frank O, Duesberg P, Hochhaus A, et al. (2005) Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 19: 1573-1578.
20. Fabarius A, Giehl M, Rebacz B, Kramer A, Frank O, et al. (2008) Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 93: 1145-1154.
21. Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, et al. (2004) Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18: 1340-1346.
22. Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W, et al. (2005) Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet 157: 53-61.
23. Nigg EA, (2007) Centrosome duplication: of rules and licenses. Trends Cell Biol 17: 215-221.
24. Nigg EA, Raff JW, (2009) Centrioles, centrosomes, and cilia in health and disease. Cell 139: 663-678.
25. Simmons Kovacs LA, Haase SB, (2010) Cohesin: it's not just for chromosomes anymore. Cell Cycle 9: 1750-1753.
26. Schockel L, Mockel M, Mayer B, Boos D, Stemmann O, (2011) Cleavage of cohesin rings coordinates the separation of centrioles and chromatids. Nat Cell Biol 13: 966-972.
27. Diaz-Martinez LA, Beauchene NA, Furniss K, Esponda P, Gimenez-Abian JF, et al. (2010) Cohesin is needed for bipolar mitosis in human cells. Cell Cycle 9: 1764-1773.
28. Tsou MF, Wang WJ, George KA, Uryu K, Stearns T, et al. (2009) Polo kinase and separase regulate the mitotic licensing of centriole duplication in human cells. Dev Cell 17: 344-354.
29. Nakamura A, Arai H, Fujita N, (2009) Centrosomal Aki1 and cohesin function in separase-regulated centriole disengagement. J Cell Biol 187: 607-614.
30. Zhang N, Ge G, Meyer R, Sethi S, Basu D, et al. (2008) Overexpression of Separase induces aneuploidy and mammary tumorigenesis. Proc Natl Acad Sci U S A 105: 13033-13038.
31. Chestukhin A, Pfeffer C, Milligan S, DeCaprio JA, Pellman D, (2003) Processing, localization, and requirement of human separase for normal anaphase progression. Proc Natl Acad Sci U S A 100: 4574-4579.
32. Clift D, Bizzari F, Marston AL, (2009) Shugoshin prevents cohesin cleavage by PP2A(Cdc55)-dependent inhibition of separase. Genes Dev 23: 766-780.
33. Waizenegger I, Gimenez-Abian JF, Wernic D, Peters JM, (2002) Regulation of human separase by securin binding and autocleavage. Curr Biol 12: 1368-1378.
34. Yim H, Erikson RL, (2011) Regulation of the final stage of mitosis by components of the pre-replicative complex and a polo kinase. Cell Cycle 10: 1374-1377.
35. Holland AJ, Taylor SS, (2006) Cyclin-B1-mediated inhibition of excess separase is required for timely chromosome disjunction. J Cell Sci 119: 3325-3336.
36. Meyer R, Fofanov V, Panigrahi A, Merchant F, Zhang N, et al. (2009) Overexpression and mislocalization of the chromosomal segregation protein separase in multiple human cancers. Clin Cancer Res 15: 2703-2710.
37. Pati D, (2008) Oncogenic activity of separase. Cell Cycle 7: 3481-3482.
38. Barnes DJ, Schultheis B, Adedeji S, Melo JV, (2005) Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 24: 6432-6440.
39. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, et al. (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50: 551-603.
40. Deininger M, Buchdunger E, Druker BJ, (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653.
41. Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, et al. (2005) Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 65: 8912-8919.
42. Simanovsky M, Berlinsky S, Sinai P, Leiba M, Nagler A, et al. (2008) Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia. Differentiation 76: 908-922.
43. Wasch R, Engelbert D, (2005) Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 24: 1-10.
44. Wang Y, Ji P, Liu J, Broaddus RR, Xue F, et al. (2009) Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 8: 8.
45. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, et al. (2003) The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88: 1889-1896.
46. Peters JM, (2002) The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell 9: 931-943.
47. Zachariae W, Nasmyth K, (1999) Whose end is destruction: cell division and the anaphase-promoting complex. Genes Dev 13: 2039-2058.
48. Park KH, Choi SE, Eom M, Kang Y, (2005) Downregulation of the anaphase-promoting complex (APC)7 in invasive ductal carcinomas of the breast and its clinicopathologic relationships. Breast Cancer Res 7: R238-247.
49. Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, et al. (2003) Chronic myelogenous leukemia molecular signature. Oncogene 22: 3952-3963.
50. Fang G, (2002) Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol Biol Cell 13: 755-766.
51. De Braekeleer E, Douet-Guilbert N, Rowe D, Bown N, Morel F, et al. (2011) ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol 86: 361-371.
52. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, et al. (2006) Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20: 1767-1773.
53. Rossi MR, Masters JR, Park S, Todd JH, Garrett SH, et al. (2001) The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect 109: 801-808.
54. Basu D, Zhang N, Panigrahi AK, Horton TM, Pati D, (2009) Development and validation of a fluorogenic assay to measure separase enzyme activity. Anal Biochem 392: 133-138.